Drug Profile
TAS 5315
Alternative Names: TAS-5315Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis; Urticaria
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Jun 2022 Phase-II clinical trials in Urticaria (Treatment-resistant) in Japan (PO) (NCT05335499)
- 19 Apr 2022 Taiho Pharmaceutical plans a phase IIa trial for Urticaria (Treatment-resistant) in Japan (PO) in May 2022 (NCT05335499)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in Japan (PO)